Richard Whitley to Mice
This is a "connection" page, showing publications Richard Whitley has written about Mice.
Connection Strength
0.243
-
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol. 2012 May; 86(9):5304-13.
Score: 0.035
-
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine. 2006 Mar 06; 24(10):1644-52.
Score: 0.022
-
Genetically engineered human herpes simplex virus in the treatment of brain tumours. Herpes. 2001 Mar; 8(1):17-22.
Score: 0.016
-
Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Ther. 1998 Jan; 5(1):121-30.
Score: 0.013
-
Evaluation of genetically engineered herpes simplex viruses as oncolytic agents for human malignant brain tumors. Cancer Res. 1997 Apr 15; 57(8):1502-9.
Score: 0.012
-
The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors. Proc Natl Acad Sci U S A. 1996 Oct 15; 93(21):11313-8.
Score: 0.012
-
Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc Natl Acad Sci U S A. 1995 Feb 28; 92(5):1411-5.
Score: 0.011
-
Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther. 2014 Nov; 21(11):984-90.
Score: 0.010
-
Production of bioactive soluble interleukin-15 in complex with interleukin-15 receptor alpha from a conditionally-replicating oncolytic HSV-1. PLoS One. 2013; 8(11):e81768.
Score: 0.010
-
Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J Clin Invest. 1993 Jun; 91(6):2837-43.
Score: 0.010
-
Herpes simplex vaccines. Biotechnology. 1992; 20:223-54.
Score: 0.009
-
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother. 2009 Dec; 53(12):5251-8.
Score: 0.007
-
Protection against herpetic ocular disease by immunotherapy with monoclonal antibodies to herpes simplex virus glycoproteins. Intervirology. 1988; 29(1):39-49.
Score: 0.007
-
HIV-1(89.6) Gag expressed from a replication competent HSV-1 vector elicits persistent cellular immune responses in mice. Vaccine. 2007 Sep 17; 25(37-38):6764-73.
Score: 0.006
-
Protective immunity against herpetic ocular disease in an outbred mouse model. Curr Eye Res. 1987 Jan; 6(1):167-71.
Score: 0.006
-
Passive immunization with monoclonal antibodies against herpes simplex virus glycoproteins protects mice against herpetic ocular disease. Curr Eye Res. 1987 Jan; 6(1):173-7.
Score: 0.006
-
Engineered herpes simplex virus expressing bacterial cytosine deaminase for experimental therapy of brain tumors. Cancer Gene Ther. 2007 Jan; 14(1):45-56.
Score: 0.006
-
Serial passage through human glioma xenografts selects for a Deltagamma134.5 herpes simplex virus type 1 mutant that exhibits decreased neurotoxicity and prolongs survival of mice with experimental brain tumors. J Virol. 2006 Aug; 80(15):7308-15.
Score: 0.006
-
Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol. 2005 Jul; 7(3):213-24.
Score: 0.005
-
Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 2005 Apr; 12(4):359-68.
Score: 0.005
-
The use of a genetically engineered herpes simplex virus (R7020) with ionizing radiation for experimental hepatoma. Gene Ther. 2002 Jan; 9(1):75-80.
Score: 0.004
-
Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci U S A. 2000 Feb 29; 97(5):2208-13.
Score: 0.004
-
Effect of recombinant human interferon alpha B/D (rHu-IFN-alpha B/D) in combination with acyclovir in experimental HSV-1 encephalitis. Antiviral Res. 1999 Nov; 44(1):75-8.
Score: 0.004
-
Ionizing radiation improves survival in mice bearing intracranial high-grade gliomas injected with genetically modified herpes simplex virus. Clin Cancer Res. 1999 Jun; 5(6):1517-22.
Score: 0.004
-
Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors. Cancer Res. 1999 May 01; 59(9):2055-8.
Score: 0.004
-
Developmental aspects of adenine arabinoside for parenteral therapy of human herpesvirus infections. Adv Ophthalmol. 1979; 38:288-96.
Score: 0.004
-
Differential effect of recombinant human and mouse interferons on replication of herpes simplex virus type 1 in mouse cells. Antiviral Res. 1996 Aug; 32(1):27-34.
Score: 0.003
-
Humanized antibodies for antiviral therapy. Proc Natl Acad Sci U S A. 1991 Apr 01; 88(7):2869-73.
Score: 0.002